RecruitingPhase 2NCT05904106

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Studying Inherited acute myeloid leukemia

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Technische Universität Dresden
Principal Investigator: Christoph Röllig, Prof.
Technische Universität Dresden, Medical Faculty Carl Gustav Carus
Intervention: Venetoclax plus Azacitidine(drug)
Enrollment: 146 target
Eligibility: 18-70 years · All sexes
Timeline: 2024 – 2028

Study locations (18)

Universitätsklinikum Essen, Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Aachen, Aachen, Germany
Universitätsklinikum Augsburg, Augsburg, Germany
Klinikum Chemnitz gGmbH, Chemnitz, Germany
Universiätsklinikum Köln, Cologne, Germany
Universitätsklinikum Dresden, Dresden, Germany
Universitätsklinikum Erlangen, Erlangen, Germany
Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
Universitätsklinikum Halle, Halle, Germany
Universitätsklinikum Heidelberg, Heidelberg, Germany
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Universitätsklinikum Leipzig, Leipzig, Germany
Klinikum Mannheim gGmbH, Mannheim, Germany
Philipps-Universität Marburg Fachbereich Medizin, Marburg, Germany
Universitätsklinikum Münster, Münster, Germany
+3 more locations on ClinicalTrials.gov

Collaborators

University Hospital Heidelberg · AbbVie

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05904106 on ClinicalTrials.gov

Other trials for Inherited acute myeloid leukemia

Additional recruiting or active studies for the same condition.

See all trials for Inherited acute myeloid leukemia →

← Back to all trials